Mizuho downgraded Vigil Neuroscience (VIGL) to Neutral from Outperform with a price target of $8, down from $13, following the company’s acquisition by Sanofi (SNY). The firm does not expect another bid to emerge.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Hold from Buy at Jefferies
- Vigil Neuroscience downgraded to Neutral from Outperform at Wedbush
- Vigil Neuroscience Enters Merger Agreement with Sanofi
- Vigil Neuroscience downgraded to Neutral from Buy at Guggenheim
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair